Drug
Ganaplacide clinical trials
Also written KAF156.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Lumefantrine (3) · Efavirenz (1) · Midazolam (1) · Repaglinide (1) · Dextromethorphan (1) · Metformin (1) · Rosuvastatin (1) · Dolutegravir (1)
Studies
Open first, then newest update. How each study uses ganaplacide is read from its arms, and is right about nine times in ten.
Testing it · 7
- Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum MalariaCompletedPhase 2Novartis PharmaceuticalsNCT04546633Written as KAF156
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With EfavirenzCompletedPhase 1Novartis PharmaceuticalsNCT05330273Written as Ganaplacide
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and DolutegravirCompletedPhase 1Novartis PharmaceuticalsNCT05236530Written as Ganaplacide
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With ItraconazoleCompletedPhase 1Novartis PharmaceuticalsNCT05084651Written as Ganaplacide
- Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum MalariaCompletedPhase 2Novartis PharmaceuticalsNCT03167242Written as KAF156
- Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge ModelCompletedPhase 1Novartis PharmaceuticalsNCT04072302Written as KAF156
- Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infectionCompletedPhase 2Novartis PharmaceuticalsNCT01753323Written as KAF156
Codes
What other systems call ganaplacide · ClinicalTrials.gg INT000278
- MeSH (NLM) C000599914ganaplacideOne source NLM
- UNII (FDA) 85VMN9JU7AGANAPLACIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q28209255ganaplacideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175070GanaplacideOne source FDA
- DrugBank DB16173One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599914 | ganaplacide | One source NLM |
| UNII (FDA) | 85VMN9JU7A | GANAPLACIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q28209255 | ganaplacide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175070 | Ganaplacide | One source FDA |
| DrugBank | DB16173 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.